Rheumatoid Arthritis (RA) affects 50 million people worldwide. Available therapeutic options focus on treating symptoms but do little to slow disease progression. This is primarily due to the mechanism of action of current medications which are not specific to the pathogenesis of RA. Biologics targeting inflammatory cytokines currently dominate the market and provide relief to many. However, the high cost of biologics makes this therapy inaccessible to some patients and is a burden on the healthcare system. Novel inexpensive therapies are needed to slow disease progression of RA.
Peptidomimetics developed for RA
Researchers have identified a specific interaction between SE-CRT which has been demonstrated to play a direct pathogenic role in inflammatory arthritis. This deeper understanding of the pathogenesis of RA enabled researchers to identify this target and develop a novel peptidomimetic to inhibit SE-activated signaling. In mouse models, the peptidomimetic demonstrates efficacy as a therapeutic to prevent bone destruction in RA and other diseases.
- Rheumatoid arthritis
- Periodontal disease
- Erosive bone conditions
- Inexpensive synthesis
- Effective for prophylaxis and treatment
- Specific mechanism of action